Skip to main content
. Author manuscript; available in PMC: 2014 Aug 16.
Published in final edited form as: Circ Res. 2013 Jul 12;113(5):10.1161/CIRCRESAHA.113.301225. doi: 10.1161/CIRCRESAHA.113.301225

Figure 7. MEK inhibition prolongs survival and improves cardiac function in 40 kD expressing mice.

Figure 7

Mice were treated with U0126, a pharmacologic inhibitor of MAPK/ERK kinase 1/2 that blocks phosphorylation of ERK1/2. At 12 weeks of age, cardiac function was assayed by M-Mode echocardiography for the NTG (n=5), 40 kD single TG (n=5), tTA (n=11), untreated DTG (n=5) and treated DTG (n=9). A, Survival curves of DTG (n=16) untreated and U0126 treated (n=15) mice. B, Fractional shortening (FS). C, Left ventricular mass (LV mass) D, Volume of diastole. Values represent mean±SE for each group. ***P<0.001 DTG untreated versus NTG, 40 kD, tTA controls **P<0.01 treated DTG versus untreated DTG. ****P<0.0001.